STOCKS TO BUY: We have identified several stocks that can potentially TRIPLE. Learn more!

Jim Silverman

Contributor

Email This Author

Jim Silverman is the managing member of RRC Bio Fund LP, a Boston-based hedge fund focused on small-cap biotech. RRC Bio was launched in 2007. Silverman also founded Risk/Reward Capital Management in 1997, a registered investment advisory. He lives in Cambridge, Mass., and received a BBA in finance from The George Washington University.

Jim Silverman
By This Author:
« Back
Page 1 of 1
Next »
Article

Cell Therapeutics: Addicted to Reverse Stock Splits

By Jim Silverman

Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.

Related Topics: Biotech | Drugs | Health Care

10:00AM 04/18/13

Article

Programmed Insider Buying? Yes, at Insmed and United Therapeutics

By Jim Silverman

Instead of selling stock whenever the wind blows, biotech execs should be buying.

Related Topics: Biotech | Drugs | Health Care

08:00AM 01/24/13

Article

Genta: 1998-2012

By Jim Silverman

The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.

Related Topics: Biotech | Drugs | Health Care | Business News

07:00AM 10/25/12

Article

Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data

By Jim Silverman

How best to invest in the next important clinical trial catalyst facing Celgene.

Related Topics: Biotech | Drugs | Health Care

08:07AM 09/25/12

« Back
Page 1 of 1
Next »

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
TRY IT FREE
New! $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 15,112.19 -206.04 -1.35%
NASDAQ 3,443.20 -38.98 -1.12%
S&P 500 1,628.93 -22.88 -1.39%
US 10 Yr 2.311% +0.129

Brokerage Partners
Advertising Partners

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Manage Newsletters

Top Rated Stocks Top Rated Funds Top Rated ETFs